SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome–positive cells derived from patients with chronic myeloid leukemia

Nicola Esposito(Ceinge Biotecnologie Avanzate (Italy)), Fabrizio Pane(Federico II University Hospital)

Blood

August 5, 2011

10.1182/blood-2011-03-341073

Cited by 47

Related Papers

Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement

|Cancer|2013|143

Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology

|European Journal of Heart Failure|2024|64

Diagnostic capabilities, clinical features, and longitudinal <scp><i>UBA1</i></scp> clonal dynamics of a nationwide <scp>VEXAS</scp> cohort

|American Journal of Hematology|2023|43

Methodology and clinical utility of longitudinal <scp><i>UBA1</i></scp> tracking in <scp>VEXAS</scp> syndrome

|British Journal of Haematology|2024|10

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI)

|Cancer|2025|10